All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
On December 16, 2020, the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, KTE-X19, was granted conditional marketing authorization by the European Commission for the treatment of adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who have received ≥ 2 prior lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor.
This decision was based on positive results from the pivotal phase II ZUMA-2 trial (NCT02601313), evaluating the use of autologous anti-CD19-transduced CD3+ cells for the treatment of patients with R/R MCL who had previously received anthracycline- or bendamustine-containing chemotherapy, an anti-CD20 antibody therapy, and a Bruton’s tyrosine kinase inhibitor. The ZUMA-2 trial has met its primary endpoint, with 93% of patients responding to a single infusion of the anti-CD19-transduced CD3+ cells, and 67% of patients achieving a complete response. KTE-X19 formerly received a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in October 2020, and accelerated U.S. Food and Drug Administration (FDA) approval for the treatment of R/R MCL in July 2020.
Patients with MCL who relapse after or are refractory to initial therapies have a poor prognosis and treatment options are limited. KTE-X19 is the first CAR T-cell therapy for patients with R/R MCL, and its conditional approval represents a positive step forward by providing a new option for the treatment of these patients in Europe.
Gilead. Kite’s Tecartus™ (KTE-X19) granted conditional marketing authorization for the treatment of relapsed or refractory mantle cell lymphoma in Europe. https://www.gilead.com/news-and-press/press-room/press-releases/2020/12. Published Dec 16, 2020. Accessed Dec 17, 2020.
Results from the phase II ZUMA-2 trial: CAR T therapy for MCL
During the 61st ASH Meeting & Exposition, Michael Wang presented the interim results from the ZUMA-2 trial investigating the efficacy and safety of KTE-X19 in patients with R/R MCL.
Review | Therapies available or in clinical development for patients with aggressive mantle cell lymphoma in 2020
Chemoimmunotherapy with rituximab followed by autologous stem cell transplant (auto-HSCT) has been the gold standard and the only...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox